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Targeted cancer therapynd drug resistance remain major obstacles in the treatment of cancer. Therefore,
more research on the mechanisms of these processes in disease is warranted for improved treatment options.
Recent evidence suggests that the capability to sustain tumor growth and metastasis resides in a
subpopulation of cells, termed cancer stem cells or tumor-initiating cells. Continuous proliferation and self-
renewal are characteristics of stem/progenitor cells. Telomerase and the maintenance of telomeres are key
players in the ability of stem and cancer cells to bypass senescence and be immortal. Therefore, telomerase
inhibitors have the therapeutic potential for reducing tumor relapse by targeting cancer stem cells and other
processes involved in metastasis. Herein we review the role of telomerase in the immortal phenotype of
cancer and cancer stem cells, targeting telomerase in cancer, and discuss other opportunities for telomerase
inhibitors to target critical steps in cancer metastasis and recurrence.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
In 2000, Hanahan and Weinberg listed “hallmarks” of cancer that
must be considered in order to understand the underlying determi-
nants of carcinogenesis: a) self-sufﬁciency in growth signals; b)
insensitivity to growth-inhibitory (anti-growth) signals; c) evasion of
programmed cell death (apoptosis); d) limitless replicative potential;
e) sustained angiogenesis; and f) tissue invasion and metastasis [1].
Advances in diagnostics and treatment have signiﬁcantly reduced
mortality from primary cancers by successfully hitting some of the
cancer hallmarks. Unfortunately, most deaths from cancer are due to
metastases and tumor relapse in which the tumors display resistance
to standard therapies [2]. Within the last few decades, an expansion of
research on cancer metastasis, angiogenesis, and replicative potential
has led to increased understanding of these processes and new
developments in therapeutic targeting and potential biomarkers.tacted at the Department of
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ll rights reserved.Metastasis is the ability of the cancer to spread from its origin to
distant locations within the body and continue to grow [reviewed in
2]. Metastasis depends on the cancer cells acquiring increased
motility and invasiveness. More speciﬁcally, the main steps in
metastasis include: proliferation and angiogenesis; detachment and
local invasion into the stroma; detachment and circulation of tumor
cells; adherence of tumor cells at secondary sites (on capillary
endothelial cells or a basement membrane); extravasation; and,
proliferation/survival and angiogenesis at distant sites. As described
in more detail later in this review, angiogenesis is an early step in the
formation of a metastasis in which extensive vascularization must
occur to allow tumors to feed and grow [2]. Several growth factors as
well as the endothelial cell population play key roles in sustaining
angiogenesis and therefore can be subjected to targeting by
therapeutics.
The hallmark of limitless replicative potential in cells is driven by
the maintenance of telomeres. Telomeres are hexameric DNA
sequences (TTAGGG) found at the ends of chromosomes to prevent
end to end fusions and help to maintain genomic stability [3]. The
telomere is also a complex structure consisting of a 3′ G-rich
overhang, which wraps around to form a protective telomere loop
(t-loop), and its associated capping proteins, collectively termed the
telosome or shelterin [3–6]. Telomeres in the majority of normal
human cells shorten with each cellular division due to the “end-
replication problem.” Since DNA polymerase can only initiate
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fully synthesize the 3′ terminal end of the lagging strand of linear DNA
(which is based on a series of Okazaki fragments). The result is an end-
replication problem in which terminal DNA is lost with each round of
division. Once telomeres have shortened to a certain length, cells with
intact cellular checkpoint controls (e.g., p53/Rb) undergo replicative
senescence [reviewed in 3,4,7]. Cells that have lost critical checkpoint
controls can bypass senescence and their telomeres continue to
shorten. During this crisis period of cell proliferation and death due to
short telomeres, cell death usually prevails which can limit cellular
lifespan. In rare instances, the presence of critically short or
dysfunctional telomeres can result in end fusions and genomic
instability, which can lead to a cell acquiring mutations and the
ability to progress towards cancer.
Cellular senescence is the ultimate and irreversible loss of
replicative capacity occurring in primary somatic cell culture. The
shortening of telomeres is thought to function as a replicometer that
counts the ﬁnite number of cell divisions and triggers replicative
senescence in normal diploid cells [8]. In the majority of human
malignancies, maintenance of telomeres is achieved by reactivation of
telomerase, an enzyme that counteracts telomere shortening, over-
comes senescence and leads to cell immortalization [9]. A smaller
fraction of tumors (10–15%) use an alternative recombination-based
mechanism termed ALT (alternative telomere lengthening) pathway
[10]. Although the mechanisms involved in the decision of a cell to
activate either telomerase or ALT are unknown at present, the ALT
pathway is more commonly activated in tumors of mesenchymal
origin and the presence of the ALT phenotype is associated with poor
prognosis [11].
The activity of telomerase to synthesize and maintain telomeres is
reliant on the expression of both the RNA component (hTR) and the
catalytic subunit (hTERT), the regulation of which is tightly
coordinated on multiple levels by transcriptional, post-transcrip-
tional, translational, and epigenetic mechanisms [12,13]. During early
embryonic development, hTERT is transcriptionally repressed and
subsequently most human somatic cells have undetectable telomer-
ase activity. However, germline cells, stem cells, and progenitor cells
exhibit telomerase activity [14]. Ectopic expression of hTERT in
normal human cells leads to extension of life-span or immortaliza-
tion of many cell types [15]. Additionally, constitutive expression of
TERT in cancer-resistant mice, engineered by enhanced expression of
the tumor suppressors p53, p16, and p19ARF, produces a systemic
delay in aging accompanied by extension of the median life span [16].
In summary, telomerase plays a critical role in the immortal
phenotype of cells that have indeﬁnite proliferative potential, such
as stem/progenitor cells (including the putative cancer stem cells)
and cancer cells.
This review focuses on the targeting of telomerase and the
immortal phenotype in cancer using telomerase template antago-
nists. One such antagonist, GRN163L, has been shown to act as a
potent telomerase inhibitor with additional properties that may
affect cancer cell adhesion, new vessel formation, metastasis, and
drug resistance. Furthermore, telomerase has been implicated to
possess extracurricular activities in replicative aging and cell survival
beyond telomere maintenance [14]. Telomerase may be directly or
indirectly involved in apoptosis (via mitochondria homeostasis or
membrane potential), DNA damage response, stem cell and organism
ﬁtness, and regulation of chromatin architecture or gene expression
(including genes involved in cell signaling, cell cycle, metabolism, cell
death/differentiation, and growth factors) [14]. Therefore, while one
should caution the use of telomerase as a universal and safe target for
cancer therapy if normal cells may be affected, there may be
increased therapeutic potential for telomerase antagonists in the
ﬁght against cancer metastasis and recurrence. Based on emerging
data, we discuss the potential of telomerase antagonists for targeting
cancer stem cells, hypothesized to play a major role in tumorrecurrence and metastasis, as well as targeting angiogenesis, a critical
step in metastasis.
2. Targeting telomerase and the immortal phenotype in cancer
using telomerase template antagonists
Telomerase and the maintenance of telomeres are key players in
the ability of cells to bypass senescence and be immortal. Preclinical
and clinical evidence have supported the rationale of targeting
telomerase as a novel form of cancer therapy [reviewed in 17]. The
majority of cancer cells have increased hTERT expression, telomerase
activity, and shorter telomere lengths compared to neighboring
tissue and most normal cells. The telomerase complex offers several
opportunities for targeting, such as genetic manipulation of expres-
sion, template antagonism or direct enzymatic inhibition [18,19]. One
such target is the telomerase RNA component, hTR, which is required
for the RNA-dependent reverse transcriptase function of hTERT. The
steps involved in synthesizing telomeres by telomerase include: 1)
the binding of the short C-rich template sequence region of hTR to
the G-rich telomeric strand by Watson–Crick base pairing; 2)
elongation of the telomere by hTERT, in which six nucleotides
(GGTTAG) are added sequentially, driven by the template sequence
of hTR; and, 3) translocation of the telomere-template heteroduplex
to position it for another round of elongation (processive addition).
This process can be disrupted when the extended telomere is
dissociated from telomerase [17]. The hTR is not translated into
peptides; therefore, oligonucleotides complementary to the hTR
template region block the active site of hTERT reverse transcriptase
and act as competitive enzyme inhibitors (or template antagonists).
Furthermore, since hTERT may have other functions in cell survival
independent of its activity [14], targeting hTR and designing direct
enzymatic inhibitors will maintain hTERT expression in the cell.
Since 1995, many laboratories have shown, through extensive
research, the proof of principle that targeting hTR results in the
inhibition of telomerase activity, progressive telomere shortening,
and subsequent death of immortalized or cancer cells in vitro
[reviewed in 17–19]. Preclinical animal studies have also demon-
strated that telomerase template antagonists are effective in
reducing the primary growth in a variety of cancers (lung, prostate,
breast, ovarian, glioblastoma, leukemia, lymphoma, myeloma, for
example). Furthermore, several studies suggest that telomerase
template antagonists can reduce the metastasis index in animal
models [20–22]. However, the mechanisms for the reduction in
metastases are not completely understood. The direct telomere-
shortening effects of GRN163L on the tumor cells themselves might
be sufﬁcient to explain these effects on metastasis as massive
numbers of cell divisions are required for metastases to form from
single invading cells. On the other hand, reduction in cell growth due
to targeting the shortest telomere in a cell may result in a bystander
effect on the population, or potential telomere-independent effects
by the telomerase template antagonists.
Several methods for targeting the hTR to inhibit telomerase
activity have been tested [18]. These include antisense oligonucleo-
tides, peptide nucleic acids (PNAs) and chemically modiﬁed PNAs, 2′-
O-methyl RNA (2′-O-MeRNA) and 2′-O-methoxyethyl RNA (MOE
RNA), phosphorothioate (PS), N3′-P5′ phosphoramidate (NP), and
N3′-P5′ thio-phosphoramidate (NPS) DNA. Further development of
NPS oligonucleotides has led to the ﬁrst telomerase template
antagonist, GRN163L, to reach clinical trials.
2.1. GRN163L: a potent telomerase template antagonist with additional
properties?
The telomerase inhibitor GRN163L is a 13-mer oligonucleotide
N3′→P5′-thio-phosphoramidate lipid conjugate and represents the
latest generation of modiﬁed oligonucleotides targeting hTR [23].
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are an oligonucleotide thio-phosphoramidate and a lipid group.
These moieties are connected via a short amino glycerol linker
(Fig. 1). The oligonucleotide portion of the conjugate has the
nucleoside sequence 5′-TAGGGTTAGACAA-3′, which is complemen-
tary to the template region of hTR and designated as GRN163. The
3′-terminal adenosine contains a 3′-amino group (estimated pKa
value of ∼9), which should be mainly protonated under physio-
logical conditions at pH 7.4. All the composing nucleosides contain
3′-amino groups and the non-bridging oxygen atom of the
internucleoside phosphoramidate monoester groups uniformly
substituted with a sulfur atom (see chemical structure in Fig.
2B). Hence, all the internucleoside linkages of this molecule are
N3′→P5′-thio-phosphoramidates. This is one of the key distin-
guishing features of GRN163L compared to other oligonucleotides,
containing either natural phosphodiester, or phosphorothioate, or
N3′→P5′ phosphoramidate internucleoside groups — see Figs. 2C, D
and A respectively, and the text below. GRN163L also contains one
phosphorothioate diester group tethering the lipid amino glycerol
and the oligonucleotide domains (see chemical structure in Fig. 1).
All the internucleoside thio-phosphoramidate as well as the linking
phosphorothioate groups are ionized and negatively charged under
physiological conditions. GRN163L is currently synthesized and
used as all-sodium salt with molecular weight of 4895 g/mol, and
4609 g/mol for the all-acid form. The compound is also well-
soluble either in water or in saline solution, making this compound
translatable to the clinic.Fig. 1. Chemical structure and functionally important features of GRN163L. Space ﬁlling
molecular model and chemical structure of the telomerase inhibitor oligonucleotide
N3′→P5′-thio-phosphoramidate GRN163L with the nucleoside sequence 5′-TAGGGT-
TAGACAA-3′. All internucleoside linkages are 3′-NH-P(O)(S-)-O-5′-thio-phosphorami-
date monoesters, and the oligonucleotide contains a 3′-terminal amino group (-3′-NH2).
All sulfur (=S) atoms are in yellow; the 3′-amino (-NH-) groups of the thio-
phosphoramidate linkages are in blue; the palmitoyl (C16) lipid group is attached to the
5′-terminus via 3-amino glycerol linker (in the molecular model the palmitoyl group is
folded back towards the oligonucleotide bases).The presence of thio-phosphoramidate internucleoside linkages in
GRN163L provides for high thermodynamic stability of its complex
with the targeted telomerase hTR [24–26]. Thus, the melting
temperature (Tm) of a duplex formed by GRN163L and a complemen-
tary RNA strand is 69.5 °C under close to physiological conditions, in
PBS. For comparison, Tm of the duplexes formed by either iso-
sequential phosphodiester DNA (Fig. 2C) or phosphorothioate
(Fig. 2D) 13-mer oligonucleotides is 45.2 °C or 40.5 °C, correspond-
ingly. Moreover, thio-phosphoramidate linkages are very resistant to
cellular nuclease hydrolysis, providing for a long half-life of the intact
GRN163L in vitro and in vivo. At the same time, in cell-free assays, an
N3′→P5′ phosphoramidate oligonucleotide is approximately 5–10
times less potent of a telomerase inhibitor than its iso-sequential thio-
phosphoramidate counterpart, GRN163 (compare Fig. 2A, B). This
difference in activity was attributed to possible secondary (to
Watson–Crick type hydrogen bonding) interactions between sulfur
atoms of the sugar-phosphate backbone and the hTERT subunit of
telomerase [24–26]. Importantly, the presence of the covalently
conjugated 5′-palmitic lipid group provides for better cellular up-
take and higher bio-availability of GRN163L vs. GRN163 molecules. In
the majority of cancer cell lined tested, IC50 values for telomerase
inhibition were at least 5–10 times lower for GRN163L than that for
GRN163. A similar trend was also observed in various in vivo animal
model systems, where GRN163L demonstrated high anti-telomerase
activity [17,23] for review].
It has been extensively reported that G-quadruplex forming
oligonucleotides (either with phosphodiester or phosphorothioate
linkages) can efﬁciently bind to various structurally important intra-
and extra-cellular proteins and thus alter their functions [reviewed in
27]. These interactions are determined, in part, by the presence of G-
quadruplex structures, which may be recognized by protein ligands as
structural pharmacophore groups. For example, a phosphorothioate
octamer d-(TTGGGGTT), designated as ISIS 5320 (ISIS Pharmaceuti-
cals Inc.) forms an all-strands parallel G-quadruplex structure, which
efﬁciently binds to the HIV envelope glycoprotein gp120, and thus
inhibits both cell-to-cell and virus-to-cell infections [28]. Our
preliminary physico-chemical data indicate that, in addition to the
formation of thermodynamically stable and sequence-speciﬁc
duplexes with hTR, GRN163L is capable of forming rather stable G-
quadruplex complexes under close to physiological conditions. This
was determined using thermal dissociation experiments, where the
change in the UV-absorption spectra was monitored at a 295 nm
wavelength, which is characteristic for dissociation-association
transitions of guanine quartets (Fig. 3). Moreover, the thermal
dissociation experiments were conducted in practically iso-molar
sodium (NaCl in PBS) and potassium (0.15 M KCl) containing buffer
solutions, where strong G-quadruplex stabilizing effects of potassium
ions were observed. The melting temperatures of the G-quadruplexes
formed by GRN163L are 63.9 °C or 89.7 °C in the presence of sodium or
potassium ions, respectively (Fig. 3). The parental iso-sequential
oligonucleotide, GRN163, which lacks the 5′-lipid group, forms
noticeably less stable G-quadruplexes, with Tm of 49.7 °C and
74.5 °C, respectively, under similar experimental conditions.
GRN163L does not form stable G-quadruplex complexes in low ionic
strength solutions, i.e., in 10 mM sodium phosphate buffer, pH 7.4, or
in de-ionized water (Fig. 3).
It is estimated that the special arrangement of the G-quadruplex
formed by GRN163L is structurally similar to that formed by ISIS5320,
with all four strands being aligned in parallel orientation. This
arrangement, we believe, is the most thermodynamically stable
oligonucleotide strand orientation, due to potential lipid-lipid
stabilizing hydrophobic interactions. High resolution NMR or X-ray
structural data is currently not yet available, in part due to the
difﬁculties with crystallization of GRN163L. Formation of this G-
quadruplex is driven by the presence of the GGG-motif close to the 5′-
terminus in the molecule. The 5′-C16 palmate lipid groups further
Fig. 2. General chemical structure of internucleoside linkages for representative synthetic oligonucleotides evaluated as telomerase substrates and inhibitors. (A) internucleoside
N3′→P5′ phosphoramidate group, designated as NP; (B) internucleoside N3′→P5′ thio-phosphoramidate group, designated as NPS; (C) native DNA phosphodiester group,
designated as PO; (D) modiﬁed DNA phosphorothioate group, designated as PS. Replacement of the bridging 3′-oxygen atom in native nucleosides by 3′-amino group results in
the formation of 3′-amino-phosphoramidates (NP's); additional replacement of non-bridging oxygen atom by sulfur results in the formation of thio-phosphoramidates (NPS's).
NP- and NPS-oligonucleotides are stable to cellular nucleases, and they form thermodynamically stable duplexes with complementary RNA strands, including the telomerase hTR
domain.
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similar type of DNA duplex and triplex stabilizing effects via lipophylic
interactions was previously reported [29]. The formed duplex with
hTR is apparently more thermodynamically stable than the G-
quadruplex structure of GRN163L alone.
Additionally, there is an apparent correlation betweenG-quadruplex
formingabilityof oligonucleotidephosphoramidatesand their effects on
cellular morphology and cell adhesion properties. GRN163L has been
shown to be capable of inducing a rounding-effect on cellular
morphology and prevent cell attachment to a substrate for various cell
lines in a telomerase activity-independentmanner [22,30]. However, its
mismatch control compound (5′-Palm-TAGGTGTAAGCAA, mismatch
sequences in italics), having the same nucleoside composition, but
lacking the GGG-motif (and therefore unable to form stable G-
quadruplex, with Tm of 29.2 °C in PBS), does not affect the cell adhesion
and morphology properties under similar experimental conditions.
GRN163Lwasobserved tonothave aneffect on cell growth,morphology,
or adhesion in normal ﬁbroblasts, nonmalignant cell lines, or normal
tissues in animal models [17] and relevant references therein, [22,30].
2.2. Status of telomerase template antagonists in clinical trials
GRN163L is the most advanced direct enzymatic telomerase
inhibitor that has reached cancer therapeutic clinical trials [17]. As
described earlier, the chemistry of GRN163L allows its potential to
be transitioned to the clinic. GRN163L exhibits a higher melting
temperature, formation of stable duplexes with single-stranded RNA,resistance to degradation and drug efﬂuxmechanisms (drug resistance),
and higher afﬁnity and speciﬁcity for its target. GRN163L entered clinical
trials for cancer patients in 2005 and currently there are six trials for
multiple tumor types (chronic lymphocytic leukemia,multiplemyeloma,
lung, breast, and advanced solid tumors). Correlative studies include
investigating thenumberof circulating tumorcells,whichmayconstitute
the “seeds” for metastasis, after treatment with GRN163L. Recently,
GRN163L entered a Phase I/II clinical trial for patients with locally
recurrent or metastatic breast cancer (Trial ID: NCT00732056, www.
clinicaltrials.gov). This trial is in combination with paclitaxel, a mitotic
inhibitor, and bevacizumab, an anti-angiogenic agent and monoclonal
antibodyagainst vascular endothelial growth factor (VEGF). Important to
note is that these early stage trials do not address in depth the
combination effects of GRN163L with other forms of therapy; therefore,
the future design of combination trials is eagerly anticipated. The use of
anti-telomerase agents in clinical trials is still in its earliest stages for
complete analyses of outcomes, efﬁcacy, tolerance, and toxicity on
normal tissues [31].
3. New therapeutic potential for telomerase antagonists: targeting
critical steps in cancer metastasis and recurrence
3.1. Targeting telomerase in cancer stem cells: a potential target for
tumor recurrence and metastasis
Recent evidence has suggested that the capability to sustain tumor
growth and metastasis may reside in a small number of cells, termed
Fig. 3. Thermal dissociation and association curves for G-quadruplex formed by GRN163L. Thermal dissociation experiments were conducted using a Cary 1E spectrophotometer.
Change in UV absorbancewas recorded at 295 nm. A temperature gradient of 1 °C/minwas used for to acquire both dissociation (upper curve) and association, or re-annealing (lower
curve), where a signiﬁcant lagging effect for the re-annealing process was observed (which is characteristic for a relatively slow tetra-molecular reaction of G-quadruplex formation).
Panels A - C correspond to the dissociation-association experiments conducted in sodium (PBS), potassium (0.15 M KCl in 10mMNa-phosphate buffer) and 10mMNa-phosphate pH
7.4 buffer only, respectively.
244 Z.G. Dikmen et al. / Biochimica et Biophysica Acta 1792 (2009) 240–247cancer stem cells or tumor-initiating cells [32–34]. The cancer stem
cell population is proposed to be highly tumorigenic, to contain self-
renewal properties, to differentiate to give rise to a diverse progeny
and a heterogeneous tumor, to possess efﬁcient efﬂuxmechanisms for
drug resistance, and to undergo continuous proliferation. Cancer stem
cells have been recently identiﬁed in several cancers based on the
expression of stem cell-like cell surface markers as has been
historically utilized for hematological cell/cancer cell types [35–37].
Continuous proliferation and self-renewal upon mitogen stimulation,
in addition to telomerase activity, are also characteristics of normal
stem/progenitor cells. As a putative stem/progenitor cell population
with similar characteristics for indeﬁnite replicative potential, cancer
stem cells should be subjected to similar telomere maintenance and
telomerase regulation as other stem/progenitor cells. Interestingly,
while it has been accepted that stem/progenitor cells express
telomerase activity, stem/progenitor cells actually exhibit gradual
telomere shortening during their life-span in culture. So while the
expression of telomerase in these cells may not be sufﬁcient to
prevent telomere shortening, the expression of low levels of
telomerase activity in these cells may permit their continuous cell
turnover and overall survival or function [14]. On the other hand,recent evidence has shown that the adult stem cell compartment is
enrichedwith the longest telomeres of a tissue [38]. Consistent with in
vitro data, the telomeres were observed to shorten during age in the
normal adult stem cell compartment and this coincides with a
decrease in stem cell function during aging. Recent ﬁndings with
breast cancer cells suggest that isolated side populations of CD44+/
CD24−/low cells, which show similar characteristics and cell surface
markers of stem/progenitor cells, also exhibit telomerase activity and
short telomere lengths similar to the parental cancer cell line [37].
These results suggest that the stem cell-like tumor initiating cells may
be prime targets for telomerase inhibitor treatment as part of the
therapeutic regimen for cancer.
Li et al. have shown that the intrinsic resistance to chemotherapy in
breast cancer patients, which can result in tumor relapse, resides in a
small subpopulation of cancer stem cells [39]. Since a characteristic of
stem cells is efﬂux (such as in the efﬂux of the Hoechst dye) and drug
resistance [39,40], it is imperative to develop novel therapy that can
effectively enter these cancer stem cells and reduce tumor re-growth.
Therefore, it will be important to determine whether oligonucleotide
telomerase template antagonists, such as GRN163L, can be effectively
takenupby the putative cancer stemcells. Emerging evidence suggests
245Z.G. Dikmen et al. / Biochimica et Biophysica Acta 1792 (2009) 240–247that GRN163L can target drug-resistant cancer cells and restore
sensitivity to therapy that may be due to both telomere-dependent
and independent mechanisms [21,41]. Goldblatt et al. have shown that
GRN163L can effectively inhibit telomerase in trastuzumab-resistant
breast cancer cells, reduce cell growth in vitro, and restore sensitivity
to these breast cancer cells to trastuzumab [41]. Therefore, telomerase
inhibitors have the potential to target telomerase, telomere main-
tenance, drug resistance, and the replicative potential of cancer stem
cells for effective cancer therapy.
3.2. Potential for telomerase antagonists to target angiogenesis
Angiogenesis is required for invasive tumor growth andmetastasis
and constitutes an important point in the control of cancer progres-
sion. During tumor progression and metastasis, environmental and
genetic changes induce an “angiogenic switch” through upregulation
of angiogenic factors or downregulation of angiogenesis inhibitors.
Frequently, overexpression of angiogenic factors, such as vascular
endothelial growth factor (VEGF), allows tumors to make the
angiogenic switch. Anti-angiogenic therapy targets proliferating
endothelial cells instead of cancer cells and may reverse this
“angiogenic switch” preventing growth of tumor vasculature
[42,43]. The correlation between increased angiogenesis and poor
outcome has been established in many types of tumors such as breast
cancer, renal cancer, prostate cancer, colon cancer and melanoma
[43,44].
Telomerase, which is highly expressed in advanced stages of most
cancers, may also contribute to tumor progression through still
undeﬁned cell growth-promoting functions [14]. Vascular endothelial
cells were observed to express hTERT mRNA by in situ hybridization
on human astrocytic tumor sections [45]. Additionally, a signiﬁcant
correlation was observed between the level of hTERT mRNA expres-
sion and the proliferation rate of the endothelial cells within the
tumor vasculature as well as the histological grade of the tumor. Since
hTERT expression by vascular endothelial cells is absent in non-
neoplastic granulation tissues and in normal brain, it is possible that
diffusible angiogenic factor(s) released by the tumor might act on
the endothelial cells [45,46]. When telomerase activity was inhibited
in glioblastoma cell lines via retroviral transduction of an small-
interfering RNA (siRNA) targeting hTERT mRNA, decreased cell
proliferation, increased apoptosis, and reduced angiogenesis was
observed in the hTERT-siRNA expressing xenograft tumors com-Fig. 4. The oligonucleotide telomerase template antagonist GRN163L has potential to reduce
The anti-angiogenic effect of GRN163L on vascular development was evaluated using the CAM
Institution (Ankara, Turkey) and incubated at 37 °C and 85–90% relative humidity throughou
six eggs, and awindowwas opened in each egg to allow subsequent access to the CAM. GRN1
concentrations (5 mg/kg, 10 mg/kg, and 20 mg/kg). GRN163L solution (100 μl) was placed o
mismatch solution, and then all eggs were sealed with transparent tape. Following 48 h, CAM
The dotted circle at 48 h indicates the placement of the solution at time 0 h.pared with controls [47]. Furthermore, telomerase expression has
been shown to correlate with VEGF expression in breast carcinomas
[48]. The increase in hTERT, hTR and VEGF expression during
malignancy may also be attributed to hypoxia stimulation of
transcription [49]. Zaccagnini et al. showed that telomerase
activation is essential for the VEGF dependent vascularization of
ischemic tissue [50]. Adenovirus-mediated transfer of the wild-type
hTERT gene in ischemic rats induced development of new capillaries
whereas delivery of a dominant negative mutant of TERT failed to
promote capillarogenesis. Additionally, the inhibition of telomerase
by 3′-azido-3′-deoxythymidine (AZT) in VEGF-treated endothelial
cells strongly reduced capillary formation and failed to prevent
apoptosis [50]. Similarly, when Falchetti et al. inhibited telomerase
activity of human endothelial cells, either by RNA interference
(RNAi) or by a dominant negative allele of hTERT, tubule formation
was abolished and survival of the endothelial cells in tumor
xenografts were signiﬁcantly reduced [51].
All these ﬁndings suggest a contribution of telomerase activity to
angiogenesis. The expression of telomerase by tumor vascular cells
and endothelial progenitor cell proliferation appears to be an early
event during the tumor progression. In this view, anti-telomerase
therapy would be effective against new vessel formation by decreas-
ing proliferation of the endothelial progenitor cells in addition to
inhibiting neoplastic cell proliferation. It has been demonstrated that
telomerase-deﬁcient (Terc−/−) mice with critically short telomeres
show a striking impairment in angiogenesis. Therefore, cancer
therapies based on eliciting telomere shortening (i.e., by telomerase
inhibition) would contribute to tumor size reduction not only by a
cytolytic effect but also by slowing or preventing angiogenesis [52].
Alternatively, the emerging evidence of GRN163L's additional proper-
ties as an anti-cancer agent, in addition to its effects as an anti-
telomerase agent, may also play a role in this context. In support of
this concept, the chorioallantoic membrane (CAM) assay can be used
to determine the in vivo effects of GRN163L on blood vessel growth.
The CAM assay is well established andwidely used as an in vivomodel
to examine angiogenesis and anti-angiogenesis by topical adminis-
tration of new study agents [53]. It is an alternative approach to small
animal models and provides a natural environment of growing blood
vessels [54,55]. Preliminary ﬁndings of the CAM assay data suggest
that GRN163L at 5–10 mg/kg doses inhibits in vivo angiogenesis
without a cytotoxic effect. As shown in Fig. 4, physiological
angiogenesis was observed in the form of some allantoic vessels invascular development as demonstrated by the chorioallantoic membrane (CAM) assay.
assay [53]. For the assay, Atak-S fertilized chicken eggs were obtained from Tavukculuk
t the experiment. On day six, the eggs were divided in 4 groups, each group consisting of
63L and Mismatch control oligonucleotide solutions were prepared in PBS at 3 different
n the surface of each CAM (dotted circle, time 0 h), whereas control CAMs received only
s were screened and photographedwith a digital camera (KonicaMinolta, Tokyo, Japan).
Fig. 5. Strategies for targeting metastasis and the immortal phenotype of cancer/cancer stem cells using telomerase template antagonists.
246 Z.G. Dikmen et al. / Biochimica et Biophysica Acta 1792 (2009) 240–247the mismatch control oligonucleotide-treated eggs, whereas a
signiﬁcant reduction in CAM area was appreciable macroscopically
in the GRN163L treatment group after 48 h incubation. Although 5–
10 mg/kg GRN163L was well tolerated in these eggs, higher doses
(20 mg/kg) caused toxicity in 40% of the eggs. Considering these data
and its role as a potent telomerase inhibitor, GRN163L may have
therapeutic potential as an anti-angiogenic agent in the treatment of
cancer; however, further animal studies are needed to show that
GRN163L administration is safe and effective.
4. Conclusions and therapeutic perspectives
Although themain role of telomerase in aging and cancer has been
well documented, accumulating evidence suggests that telomerase
has important roles in angiogenesis, metastasis and cancer stem cells
in addition to its classical function in telomere length maintenance.
Continued research will identify the novel biochemical properties of
telomerase which will provide additional insights in aging and
cancer. GRN163L, as a potential G-quadruplex forming oligonucleo-
tide, may have additional anti-cancer effects beyond its function as a
telomerase inhibitor (i.e., anti-metastatic). Fig. 5 summarizes
strategies for targeting metastasis and the immortal phenotype of
cancer/cancer stem cells using telomerase template antagonists. As
these agents, as well as other telomerase-based therapies, are
currently in clinical trials, careful analysis of their effects on different
tissues should shed light on their potential as therapy as well as
insight into telomere/telomerase biology in normal, stem, and
cancer cells.
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